Viva Biotech Accelerate The Early Drug Discovery Through AI Technology

Viva Biotech President Said Integration Of AI Deep Learning Tech And SBDD Technology Platform Is Bound To Have A Far-Reaching Impact On Drug.

Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou. The conference is aiming to unite with biotech and IT industry partners to create a multi-party integrated industrial ecosystem, and realize AI’s comprehensive empowerment in the field of biotechnology.

Viva Biotech was invited to attend the conference, and announced a strategic collaboration agreement with BioMap. This collaboration will be based on the AI + biological computing engine from BioMap, with the structure-based drug discovery platform from Viva Biotech, to jointly accelerate the R & D of the novel drugs.

Dr. Delin Ren, President Of Viva Biotech, Said: “The Integration Of AI Deep Learning Technology And SBDD Technology Platform Is Bound To Have A Far-Reaching Impact On Drug Design And R & D. The strategic collaboration between Viva Biotech and BioMap is the perfect combination of these two technologies. It is expected to shorten the R & D cycle and improve the success rate of novel drug discovery.” AlxplorerBio and EPN, two biotech companies that invested and incubated by Viva BioInnovator, also attended this meeting and signed the collaboration agreement.

This news was originally published at Biospectrum Asia.

Leave a Reply

Your email address will not be published. Required fields are marked *

Captcha loading...